Alligator Bioscience AB at AACR Virtual Annual Meeting Transcript
I'm Charlotte Russell, Chief Medical Officer. On behalf of the investigators and my colleagues at Alligator Bioscience, I'm happy to present the interim data from the first-in-human Phase 1 dose-escalation study with ATOR-1015 in patients with advanced solid malignancies.
ATOR-1015 is a human bispecific antibody targeting CTLA-4 and OX40. It was developed by fusing an optimized version of CD86, one of the natural ligands to CTLA-4, to an agonistic OX40 antibody in an IgG1 format. Both CTLA-4, a checkpoint receptor expressed on regulatory T cells, and OX40, a co-stimulatory receptor on the T cells, are highly upregulated in the tumor microenvironment. So, by targeting these two receptors, ATOR-1015 has the potential to increase localization to the tumor area compared to monospecific antibodies.
The tumor localization of ATOR-1015 may reduce the risk of systemic T-cell activation and improve the efficacy. The mode of action of ATOR-1015 has been evaluated in vitro where it induces T-cell activation and depletes
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |